Sigma Planning Corp Takes Position in uniQure N.V. $QURE

Sigma Planning Corp bought a new position in uniQure N.V. (NASDAQ:QURE) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 16,900 shares of the biotechnology company’s stock, valued at approximately $276,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of QURE. Torren Management LLC acquired a new stake in shares of uniQure during the 4th quarter worth approximately $28,000. IFP Advisors Inc acquired a new position in shares of uniQure in the fourth quarter worth about $48,000. Smartleaf Asset Management LLC purchased a new stake in shares of uniQure during the 4th quarter worth about $48,000. CIBC Private Wealth Group LLC acquired a new stake in shares of uniQure during the 3rd quarter valued at about $50,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in shares of uniQure by 42.7% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,027 shares of the biotechnology company’s stock valued at $72,000 after acquiring an additional 906 shares during the period. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Stock Performance

Shares of NASDAQ:QURE opened at $40.38 on Thursday. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40. The business’s 50 day moving average price is $35.47 and its 200-day moving average price is $25.46. The firm has a market capitalization of $2.55 billion, a PE ratio of -11.60 and a beta of 0.90. uniQure N.V. has a 1 year low of $8.73 and a 1 year high of $71.50.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The firm had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $5.21 million. As a group, equities research analysts expect that uniQure N.V. will post -3.56 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of uniQure in a research note on Friday, June 26th. Wall Street Zen raised uniQure from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Barclays upgraded uniQure from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $25.00 to $65.00 in a research report on Thursday, June 18th. Cantor Fitzgerald upgraded uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 target price on the stock in a research report on Wednesday, June 17th. Finally, HC Wainwright lifted their price target on shares of uniQure from $50.00 to $80.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Twelve analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $64.17.

Insider Buying and Selling at uniQure

In related news, insider Walid Abi-Saab sold 30,000 shares of the business’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $46.42, for a total transaction of $1,392,600.00. Following the transaction, the insider directly owned 148,235 shares in the company, valued at approximately $6,881,068.70. The trade was a 16.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Matthew C. Kapusta sold 21,082 shares of the company’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $45.16, for a total transaction of $952,063.12. Following the sale, the chief executive officer directly owned 519,227 shares of the company’s stock, valued at approximately $23,448,291.32. This represents a 3.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 433,229 shares of company stock worth $17,944,799. Company insiders own 4.65% of the company’s stock.

uniQure Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.